Abozymes Completes Seed Financing Round To Fund Development Of Technology To Enable Universal Organ Transplants And Blood Transfusions
Abozymes Completes Seed Financing Round To Fund Development Of Technology To Enable Universal Organ Transplants And Blood Transfusions
06/23/22, 11:30 AM
Location
Round Type
seed
ABOzymes Biomedical Inc., today announced it has completed a substantially upsized seed financing. The funds will be used to further develop its ground-breaking proprietary platform that enables a world where a patient’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions.